Advertisement
Research Article| Volume 298, ISSUE 1-2, P101-105, November 15, 2010

Download started.

Ok

Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use

  • Young Dae Kim
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Jung Hwan Lee
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Yo Han Jung
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Hye Yeon Choi
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Chung Mo Nam
    Affiliations
    Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Jae Hoon Yang
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Han Jin Cho
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Hyo Suk Nam
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Kyung-Yul Lee
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Ji Hoe Heo
    Correspondence
    Corresponding author. Department of Neurology, Yonsei University College of Medicine, 250 Seongsan-no, Seodaemoon-gu, Seoul, 120-752, Republic of Korea. Tel.: +82 2 2228 1605; fax: +82 2 393 0705.
    Affiliations
    Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
Published:August 27, 2010DOI:https://doi.org/10.1016/j.jns.2010.07.025

      Abstract

      Background

      Hemorrhage is a major complication of thrombolytic treatment. Concerns have been raised about the risk of hemorrhage in patients having received warfarin. Therefore, different indications for thrombolytic treatment are in use for stroke patients on warfarin. However, it remains uncertain whether the prior warfarin use actually increases their risk of bleeding in patients treated with thrombolysis.

      Methods

      This study included 179 consecutive patients who had high-risk cardioembolic sources and received thrombolytic treatment. Patients were treated with intravenous thrombolytic agents, or underwent intraarterial thrombolysis if their international normalized ratio (INR) was ≤1.7. We compared the frequency of bleeding complications between patients with prior warfarin use and those without. We also investigated whether there were differences in functional outcome and recanalization rates between them.

      Results

      A prior warfarin use was present in 28 patients (15.6%). Although INR levels were higher in the prior warfarin group, the frequency of bleeding complications was not different between patients who received prior warfarin and those who did not. No differences were observed in patients with or without prior warfarin use, for successful recanalization rate (Thrombolysis in Myocardial Infarction grade 2 or 3), mortality, or modified Rankin score (≤2) at 3 months.

      Conclusions

      Thrombolytic therapy for patients who previously received warfarin and had an INR1.7 did not affect bleeding risk, clinical outcome, or recanalization rate. Our data suggest that patients with a history of prior warfarin use may be safely treated with thrombolytic agents when their INR levels are low.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adams Jr., H.P.
        • del Zoppo G.
        • Alberts M.J.
        • Bhatt D.L.
        • Brass L.
        • Furlan A.
        • et al.
        Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
        Stroke. 2007; 38: 1655-1711
        • Albers G.W.
        • Amarenco P.
        • Easton J.D.
        • Sacco R.L.
        • Teal P.
        Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
        Chest. 2008; 133: 630S-669S
        • The European Stroke Oraganisation (ESO) Executive Committee; ESO writing Committee
        Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.
        Cerebrovasc Dis. 2008; 25: 457-507
        • Han S.W.
        • Nam H.S.
        • Kim S.H.
        • Lee J.Y.
        • Lee K.Y.
        • Heo J.H.
        Frequency and significance of cardiac sources of embolism in the TOAST classification.
        Cerebrovasc Dis. 2007; 24: 463-468
        • Newman D.H.
        • Zhitomirsky I.
        The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department.
        Ann Emerg Med. 2006; 48 (9 e1.): 182-189
        • Rombouts E.K.
        • Rosendaal F.R.
        • van der Meer F.J.
        Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
        Thromb Haemost. 2009; 101: 552-556
        • De Keyser J.
        • Gdovinova Z.
        • Uyttenboogaart M.
        • Vroomen P.C.
        • Luijckx G.J.
        Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations.
        Stroke. 2007; 38: 2612-2618
        • Furlan A.
        • Higashida R.
        • Wechsler L.
        • Gent M.
        • Rowley H.
        • Kase C.
        • et al.
        Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.
        JAMA. 1999; 282: 2003-2011
        • Hacke W.
        • Kaste M.
        • Bluhmki E.
        • Brozman M.
        • Davalos A.
        • Guidetti D.
        • et al.
        Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
        N Engl J Med. 2008; 359: 1317-1329
        • Uyttenboogaart M.
        • Koch M.W.
        • Koopman K.
        • Vroomen P.C.
        • De Keyser J.
        • Luijckx G.J.
        Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke.
        Arch Neurol. 2008; 65: 607-611
        • Ay H.
        • Arsava E.M.
        • Gungor L.
        • Greer D.
        • Singhal A.B.
        • Furie K.L.
        • et al.
        Admission international normalized ratio and acute infarct volume in ischemic stroke.
        Ann Neurol. 2008; 64: 499-506
        • Lee K.Y.
        • Kim D.I.
        • Kim S.H.
        • Lee S.I.
        • Chung H.W.
        • Shim Y.W.
        • et al.
        Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.
        AJNR Am J Neuroradiol. 2004; 25: 1470-1475
        • Adams Jr., H.P.
        • Bendixen B.H.
        • Kappelle L.J.
        • Biller J.
        • Love B.B.
        • Gordon D.L.
        • et al.
        Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
        Stroke. 1993; 24: 35-41
        • The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
        Tissue plasminogen activator for acute ischemic stroke.
        N Engl J Med. 1995; 333: 1581-1587
        • Wahlgren N.
        • Ahmed N.
        • Davalos A.
        • Ford G.A.
        • Grond M.
        • Hacke W.
        • et al.
        Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.
        Lancet. 2007; 369: 275-282
        • Torn M.
        • Algra A.
        • Rosendaal F.R.
        Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk.
        Neurology. 2001; 57: 1993-1999
        • Hylek E.M.
        • Skates S.J.
        • Sheehan M.A.
        • Singer D.E.
        An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
        N Engl J Med. 1996; 335: 540-546
        • Group T.E.A.F.T.S.
        Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group.
        N Engl J Med. 1995; 333: 5-10
        • Stanley A.G.
        • Fletcher S.
        • Tan A.
        • Barnett D.B.
        Is warfarin a contraindication to thrombolysis in acute ST elevation myocardial infarction?.
        Heart. 2006; 92: 1145-1146
        • Linfante I.
        • Reddy A.S.
        • Andreone V.
        • Caplan L.R.
        • Selim M.
        • Hirsch J.A.
        Intra-arterial thrombolysis in patients treated with warfarin.
        Cerebrovasc Dis. 2005; 19: 133-135
        • Del Pace S.
        • Scheggi V.
        Acute ischaemic stroke treated with combined intra-arterial thrombolysis and intravenous tirofiban despite oral anticoagulant therapy at an international normalised ratio > or = 2.0.
        Intern Emerg Med. 2006; 1: 250-252
        • Rizos T.
        • Herweh C.
        • Jenetzky E.
        • Lichy C.
        • Ringleb P.A.
        • Hacke W.
        • et al.
        Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants.
        Stroke. 2009; 40: 3547-3551
        • Dowlatshahi D.
        • Hakim A.
        • Fang J.
        • Sharma M.
        Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the Registry of the Canadian Stroke Network.
        Int J Stroke. 2009; 4: 328-334
        • Prabhakaran S.
        • Rivolta J.
        • Vieira J.R.
        • Rincon F.
        • Stillman J.
        • Marshall R.S.
        • et al.
        Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke.
        Arch Neurol. 2010; 67: 559-563
        • Paciaroni M.
        • Agnelli G.
        • Corea F.
        • Ageno W.
        • Alberti A.
        • Lanari A.
        • et al.
        Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study.
        Stroke. 2008; 39: 2249-2256
        • van Oostenbrugge R.J.
        • Hupperts R.M.
        • Lodder J.
        Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre.
        J Neurol Neurosurg Psychiatry. 2006; 77: 375-377
        • del Zoppo G.J.
        • Higashida R.T.
        • Furlan A.J.
        • Pessin M.S.
        • Rowley H.A.
        • Gent M.
        PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
        Stroke. 1998; 29: 4-11